Trust Signals
Do peptides actually work for psoriasis?
There is proof-of-concept data in cell lines and animal models. No peptide listed here has FDA approval for psoriasis. Compared to biologics targeting IL-17 or IL-23, which achieve PASI 90 response rates above 60 to 75 percent in large RCTs, peptides are scientifically interesting but clinically unproven.
What is KPV peptide and how does it relate to psoriasis?
KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte stimulating hormone. It inhibits NF-kB and reduces IL-6, IL-8, and TNF-alpha in keratinocyte and colitis cell models. These are the same inflammatory mediators central to psoriasis plaque formation. Human topical data specific to psoriasis is absent.
Can BPC-157 help with psoriasis?
BPC-157 modulates nitric oxide pathways, reduces certain pro-inflammatory cytokines, and promotes tissue repair in animal models. The gut-skin axis hypothesis gives it indirect relevance to psoriasis. However, all supporting evidence for psoriasis is indirect and preclinical. No human psoriasis trial exists.
Is thymosin beta-4 useful for psoriasis?
TB4 reduces certain pro-inflammatory cytokines and promotes skin barrier repair. Its role in promoting keratinocyte migration creates biological ambiguity in a disease already characterized by excessive keratinocyte proliferation. Human evidence for psoriasis does not exist.
What is the role of LL-37 in psoriasis?
LL-37 is overexpressed in psoriatic plaques, where it forms complexes with self-DNA that activate TLR9 on plasmacytoid dendritic cells, initiating the innate immune cascade driving psoriasis. Exogenous LL-37 could theoretically worsen the disease, not treat it.
How do I read a COA for a research peptide?
Look for HPLC purity above 98 percent, mass spectrometry confirmation, endotoxin testing below 1 EU per mg, and an independent dated lab report with a batch number. A COA without these elements does not provide adequate safety assurance for psoriatic skin.
Can you use peptides alongside biologics for psoriasis?
There is no human safety or interaction data for combining research peptides with IL-17 inhibitors, IL-23 inhibitors, or TNF blockers. This combination should only be explored under physician supervision and cannot be recommended based on current evidence.
Does GHK-Cu help with psoriasis?
GHK-Cu modulates inflammatory gene expression in skin cell studies and reduces certain cytokines. Evidence is preclinical. No controlled human psoriasis trial has been published.
What are the risks of using research peptides for psoriasis?
Contamination-related immune flares (endotoxins activate NF-kB), unknown pharmacokinetics in psoriatic skin, no human dose-finding data, delayed access to proven therapy, and the specific risk with LL-37 of worsening disease through TLR9 activation.
How do peptides compare to biologics for psoriasis?
Biologics targeting IL-17A and IL-23 achieve PASI 90 in 60 to 80 percent of patients in large RCTs. No psoriasis-focused peptide has Phase III data. Peptides are not a substitute for biologics in moderate-to-severe psoriasis.
What does psoriasis penetration barrier mean for topical peptides?
Compounds above roughly 500 Da do not penetrate stratum corneum well passively. KPV and GHK-Cu fall below this threshold. BPC-157, thymosin beta-4, and LL-37 are far above it. Topical application of larger peptides is unlikely to deliver meaningful concentrations into psoriatic dermis without specialized delivery systems.
Sources
- Langner MD, Maibach HI. "The 500 Dalton rule for the skin penetration of chemical compounds and drugs." Bos JD, Meinardi MM. Experimental Dermatology. 2000;9(3):165-169.
- Lande R, Gregorio J, Facchinetti V, et al. "Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide." Nature. 2007;449(7162):564-569.
- Nestle FO, Kaplan DH, Barker J. "Psoriasis." New England Journal of Medicine. 2009;361(5):496-509.
- Langley RG, Elewski BE, Lebwohl M, et al. (ERASURE/FIXTURE study groups). "Secukinumab in plaque psoriasis: results of two Phase 3 trials." New England Journal of Medicine. 2014;371(4):326-338.
- Gordon KB, Strober B, Lebwohl M, et al. (IMMhance). "Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis." Lancet. 2018;392(10148):650-661.
- Pickart L, Vasquez-Soltero JM, Margolina A. "GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration." BioMed Research International. 2015:648108.
- Bhartiya D, Bhartiya D. "Alpha-MSH and its C-terminal tripeptide KPV: immunomodulatory effects." (General mechanism review; see Catania A et al., Pharmacological Reviews. 2004;56(1):1-29.)
- Sikiric P, Seiwerth S, Rucman R, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design. 2011;17(16):1612-1632.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. "Thymosin beta4: a multi-functional regenerative peptide." Expert Opinion on Biological Therapy. 2012;12(1):37-51.
- Niyonsaba F, Ushio H, Hara M, et al. "Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells." Journal of Immunology. 2010;184(7):3526-3534.
- Furue M, Furue K, Tsuji G, Nakahara T. "Interleukin-17A and keratinocytes in psoriasis." International Journal of Molecular Sciences. 2020;21(4):1275.
Related peptide guides
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →